Low-temperature plasma (LTP) jets for mass spectrometry (MS): Ion processes, instrumental set-ups, and application examples

Martínez‐Jarquín, Sandra; Winkler, Robert

doi:10.1016/j.trac.2017.01.013

Cited by 48 publications

(32 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar investigations using plasma jet for wastewater remediation have also been reported in the literature Xin et al [ 147 ]. Apart from this, plasma jet has also been used in mass spectrometry analysis for direct detection of compounds from surfaces and complex matrices [ 148 ].…”

Section: Overview Of the Plasma Processmentioning

confidence: 99%

Removal of Pharmaceutical Residues from Water and Wastewater Using Dielectric Barrier Discharge Methods—A Review

Mouele

Tijani

Badmus

et al. 2021

IJERPH

View full text Add to dashboard Cite

Persistent pharmaceutical pollutants (PPPs) have been identified as potential endocrine disruptors that mimic growth hormones when consumed at nanogram per litre to microgram per litre concentrations. Their occurrence in potable water remains a great threat to human health. Different conventional technologies developed for their removal from wastewater have failed to achieve complete mineralisation. Advanced oxidation technologies such as dielectric barrier discharges (DBDs) based on free radical mechanisms have been identified to completely decompose PPPs. Due to the existence of pharmaceuticals as mixtures in wastewater and the recalcitrance of their degradation intermediate by-products, no single advanced oxidation technology has been able to eliminate pharmaceutical xenobiotics. This review paper provides an update on the sources, occurrence, and types of pharmaceuticals in wastewater by emphasising different DBD configurations previously and currently utilised for pharmaceuticals degradation under different experimental conditions. The performance of the DBD geometries was evaluated considering various factors including treatment time, initial concentration, half-life time, degradation efficiency and the energy yield (G50) required to degrade half of the pollutant concentration. The review showed that the efficacy of the DBD systems on the removal of pharmaceutical compounds depends not only on these parameters but also on the nature/type of the pollutant.

show abstract

Section: Overview Of the Plasma Processmentioning

confidence: 99%

Removal of Pharmaceutical Residues from Water and Wastewater Using Dielectric Barrier Discharge Methods—A Review

Mouele

Tijani

Badmus

et al. 2021

IJERPH

View full text Add to dashboard Cite

show abstract

“…LTP performed the plasma sample desorption with temperature as low as 30 ° C, which does not inflict thermal damage to the sample substrates, such as human skin . Biological sample or skin can be analyzed directly by an LTP probe for some rapid qualitative analysis.…”

Section: Ms Analysis Of Clinical Biomoleculesmentioning

confidence: 99%

Mass Spectrometry Methods for In Situ Analysis of Clinical Biomolecules

Liu

et al. 2019

Small Methods

View full text Add to dashboard Cite

past few decades, great efforts and substantial progress have been made in this field, and various methods, such as colorimetric screening, [3] enzyme-linked immunosorbent assay (ELISA), [4] fluorescence, [5] polymerase chain reaction (PCR), [6] and electrochemical assays, [7] have been extensively performed in clinical laboratory tests. Although with efficiency and robustness, the majority of these methods still lack sufficient accuracy, sensitivity, and specificity for clinical diagnostic applications.The inevitable complexity and challenges of clinical biomolecules detection have encouraged researchers to continuously devote great effort to the development of new methods with accuracy, rapidity, and simplicity. Relying on its high throughput and accuracy, great sensitivity and versatility, reliable qualitative and quantitative ability, and multiplexed detection capability, mass spectrometry (MS) is exceptionally suitable for clinical analysis and blooming in modern healthcare industry in recent years. [8][9][10] MS coupled to liquid chromatography (LC) and gas chromatography (GC) is regarded as gold standards for quantitative analysis of various compounds and have been conventionally used in clinical applications such as toxicology, [11] therapeutic drug monitoring, [12] inborn error of metabolism (IEM), [13] and steroid hormone testing [14] for decades. IEMs cause high morbidity and mortality in children, and the utilization of GC-MS and LC-MS expands newborn IEMs screening from single-screening assays to simultaneously screening of various analytes (e.g., amino acids, organic acids, carnitine, and acylcarnitine) in a single run using one sample from the patient. Some reviews have summarized a number of excellent works about applications of GC-MS and LC-MS in clinical chemistry. [15,16] These hyphenated MS methods provide accurate quantification data and abundant information of clinical biomolecules, which facilitates biological behavior understanding, biomarker discovery, and prognosis evaluation. However, in most cases, these methods are conducted by using lysis of cells or tissues, which fail to provide real-time information and spatial distribution of biomolecules in their native states. On the other hand, tedious sample pretreatment (separation, purification, and redissolution) is inevitable. These series of labor intensive and time-consuming procedures may cause unpredictable sample loss and undervaluation of biomolecules. Therefore, chromatography-based MS methods are limited to achieve high-throughput, in situ, and visual clinical applications. The development of emerging Due to the significant role of clinical biomolecules in mediating biological activities and disease progressions, in situ analysis provides a great opportunity for understanding the molecular mechanisms of biological functions, facilitating medical diagnosis, clinical treatment, and prognosis. Among all the analysis methods, mass spectrometry (MS) methodologies exhibit unique features that make them exceptionally suitable for clinica...

show abstract

“…In the commercial realm, plasmas are routinely applied as robust and reproducible sources for optical emission spectra, 5,6 as well as ionized organic compounds and monoatomic ions for mass spectrometry. [7][8][9][10][11][12][13][14] Commercial inductively coupled plasmas (ICPs) operate at high power output (>1 kW) and ionize desolvated solutions or ablated geologic material. Recent advances in plasma technology demonstrate that low power plasma sources, operating at ambient or reduced pressure, perform direct desorption and ionization of molecular compounds or geologic materials in their native state, although the potential to atomize large particles remains poorly constrained.…”

Section: Introductionmentioning

confidence: 99%

“…Recent advances in plasma technology demonstrate that low power plasma sources, operating at ambient or reduced pressure, perform direct desorption and ionization of molecular compounds or geologic materials in their native state, although the potential to atomize large particles remains poorly constrained. 14 These sources typically operate at low power (3-30 W) and low gas ow rates (<1 L min À1 ), opening the potential for them to be used as in situ instruments for spaceight. Despite this progress, the ionization capabilities of these low power plasma sources for organic or elemental analysis require further characterization.…”

Section: Introductionmentioning

confidence: 99%